Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
437 stopped studies mapped to Squamous Cell Carcinoma and descendants · 91% state a reason
Over the 437 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03833167 | Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants… | Phase 3 | terminated | Feb 6, 2019 | Merck Sharp & Dohme LLC | The study stopped due to futility | Efficacy / futility |
| NCT04844073 | A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer | Phase 1 / Phase 2 | terminated | Apr 14, 2021 | Takeda | Sponsor decision based on limited anti-cancer activity of TAK-186. | Sponsor / business decision |
| NCT05316688 | A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell… | Phase 1 / Phase 2 | terminated | Apr 7, 2022 | University of Washington | Terminated due to suboptimal delineation of fluorescence between tumor and native oral cavity… | Other (stated, no rule matched) |
| NCT06790966 | Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck…(VERSATILE-003) | Phase 3 | terminated | Jan 24, 2025 | PDS Biotechnology Corp. | The study is being discontinued solely based on financial constraints and is not related to the… | Safety / toxicity |
| NCT01810913 | Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to… | Phase 2 / Phase 3 | suspended | Mar 14, 2013 | National Cancer Institute (NCI) | Other - Assessing accrual feasibility | Enrollment / accrual |
| NCT06568172 | Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the… | Phase 3 | suspended | Aug 23, 2024 | National Cancer Institute (NCI) | Other - Other | Other (stated, no rule matched) |
| NCT06990737 | Phase 2 Pragmatic Trial of Sentinel Lymph Node Biopsy (SLNB) in Patients With Clinically… | Phase 2 | withdrawn | May 25, 2025 | University of California, Davis | Poor accrual | Enrollment / accrual |
| NCT07042295 | Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in… | Phase 2 | suspended | Jun 29, 2025 | National Cancer Institute (NCI) | Other - planned analysis of safety and efficacy data | Safety / toxicity |
| NCT04949256 | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus… | Phase 3 | terminated | Jul 2, 2021 | Merck Sharp & Dohme LLC | Trial was rendered as cancelled work ongoing in the book of business. | Sponsor / business decision |
| NCT05724602 | Radiotherapy Plus Xevinapant in Older Patients With Locally Advanced Head and Neck…(RAVINA) | Phase 2 | terminated | Feb 13, 2023 | European Organisation for Research and Treatment of Cancer - EORTC | discontinuation of all ongoing studies involving xevinapant | Other (stated, no rule matched) |
| NCT05827614 | Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR…(POTENTIATE) | Phase 1 | terminated | Apr 25, 2023 | Boundless Bio, Inc. | Decision was made to halt the study based on overall clinical experience and market considerations.… | Safety / toxicity |
| NCT06477003 | Multispectral Optoacoustic Tomography in Head and Neck Squamous Cell Cancer(OUSCCMOTORX) | N/A | suspended | Jun 27, 2024 | University of Oklahoma | Administrative reasons. | Other (stated, no rule matched) |
| NCT05423197 | 89Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in HNSCC | Phase 2 | withdrawn | Jun 21, 2022 | Andrei Iagaru | logistical issues | Other (stated, no rule matched) |
| NCT03987555 | Paclitaxel Therapeutic Drug Monitoring in Cancer Patients | — | suspended | Jun 17, 2019 | Wake Forest University Health Sciences | Funding | Funding |
| NCT03412058 | Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists(CHECK'UP) | N/A | terminated | Jan 26, 2018 | UNICANCER | The study was terminated prematurely due to insufficient patient recruitment | Enrollment / accrual |
| NCT05714553 | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | Phase 1 / Phase 2 | terminated | Feb 6, 2023 | NuCana plc | The NuTide:303 study was terminated at NuCana's discretion following refinement of the NUC-3373… | Sponsor / business decision |
| NCT06022757 | Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With… | Phase 1 / Phase 2 | terminated | Sep 5, 2023 | Evopoint Biosciences Inc. | Strategic decision by Sponsor. | Sponsor / business decision |
| NCT00707473 | Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated… | Phase 2 | terminated | Jun 30, 2008 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT03114319 | Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors | Phase 1 | terminated | Apr 14, 2017 | Novartis Pharmaceuticals | Business reasons and not due to any safety concerns | Safety / toxicity |
| NCT03139058 | Prevalence of Liver Fibrosis and Cirrhosis in Patients With Squamous Cell Carcinoma of…(fibr'HOM) | N/A | terminated | May 3, 2017 | Centre Hospitalier Universitaire, Amiens | Recruitment difficulties | Enrollment / accrual |
| NCT05050162 | Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation… | Phase 2 / Phase 3 | suspended | Sep 20, 2021 | NRG Oncology | End of Initial Phase of Multi-phase protocol; closed for protocol specified analysis | Other (stated, no rule matched) |
| NCT07100925 | A Study of Tolododekin Alfa (ANK-101) in Renal Allograft Recipients With High Risk… | Phase 1 | withdrawn | Aug 3, 2025 | Ankyra Therapeutics, Inc | Strategic realignment | Sponsor / business decision |
| NCT07216833 | Decitabine and Nivolumab in Participants With Recurrent/Metastatic Squamous Cell… | Phase 1 | withdrawn | Oct 15, 2025 | Case Comprehensive Cancer Center | PI leaving the institution | Other (stated, no rule matched) |
| NCT04916002 | A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In… | Phase 2 | terminated | Jun 7, 2021 | Regeneron Pharmaceuticals | Sponsor Decision related to study drug supply | Drug supply |
| NCT05110781 | Atezolizumab Before Surgery for the Treatment of Regionally Metastatic Head and Neck… | Phase 2 | terminated | Nov 8, 2021 | University of California, Davis | Slow accrual | Enrollment / accrual |
| NCT03646461 | Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic… | Phase 2 | terminated | Aug 24, 2018 | University of California, San Diego | Lack of scientific process of cancer-related clinical intervention | Other (stated, no rule matched) |
| NCT04169074 | Immune Modulation by Abemaciclib in Head and Neck Squamous Cell Carcinoma (HNSCC). (AIM… | Phase 2 | terminated | Nov 19, 2019 | University of Arizona | Standard of care therapy for Stage III-IVA HNSCC updated in June to include neoadjuvant + adjuvant… | Other (stated, no rule matched) |
| NCT03645928 | Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors | Phase 2 | terminated | Aug 24, 2018 | Iovance Biotherapeutics, Inc. | After reviewing the available safety and efficacy data to date, Iovance concluded that the study… | Safety / toxicity |
| NCT06295809 | A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous…(INTerpath-007) | Phase 2 / Phase 3 | terminated | Mar 6, 2024 | Merck Sharp & Dohme LLC | Business reasons | Sponsor / business decision |
| NCT06870487 | A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced… | Phase 1 | terminated | Mar 11, 2025 | Pfizer | The trial was terminated for strategic business reasons; the decision was not based on any safety… | Safety / toxicity |
| NCT05983133 | A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors | Phase 1 | terminated | Aug 9, 2023 | Seagen, a wholly owned subsidiary of Pfizer | The trial was terminated for strategic reasons. The decision was not based on any safety concerns | Safety / toxicity |
| NCT03799445 | Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive… | Phase 2 | terminated | Jan 10, 2019 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT04266730 | Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With…(PANDA-VAC) | Phase 1 | suspended | Feb 12, 2020 | UNC Lineberger Comprehensive Cancer Center | Not stated | Other (stated, no rule matched) |
| NCT06974734 | A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or… | Phase 1 | terminated | May 16, 2025 | Pfizer | The trial was terminated for strategic business reasons; the decision was not based on any safety… | Safety / toxicity |
| NCT02819752 | PEmbrolizumab Combined With Chemoradiotherapy in Squamous Cell Carcinoma of the Head and…(PEACH) | Phase 1 | terminated | Jun 30, 2016 | Royal Marsden NHS Foundation Trust | funding pulled | Funding |
| NCT06110195 | Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck Cancer | Phase 1 | terminated | Oct 31, 2023 | University of Chicago | Drug no longer being developed by manufacturer | Drug supply |
| NCT03386357 | Radiotherapy With Pembrolizumab in Metastatic Head and Neck Squamous Cell Carcinoma… | Phase 2 | terminated | Dec 29, 2017 | University of Erlangen-Nürnberg Medical School | slow recruitment | Enrollment / accrual |
| NCT04234113 | Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With… | Phase 1 | terminated | Jan 21, 2020 | SOTIO Biotech AG | Due to lack of efficacy shown at the time of the interim analysis. | Efficacy / futility |
| NCT05956795 | Surveillance of Regional Nodal Basins in Patients With Primary High Risk Cutaneous… | — | terminated | Jul 21, 2023 | Johns Hopkins University | Expired in IRB | Other (stated, no rule matched) |
| NCT05296135 | Predicting Immunotherapy Efficacy in Head and Neck Squamous Cell Cancer(PREDAPT-HNSCC2) | — | withdrawn | Mar 25, 2022 | Cofactor Genomics, Inc. | No patients were recruited or enrolled in this study. | Enrollment / accrual |
| NCT05566223 | CISH Inactivated TILs in the Treatment of NSCLC(CheckCell-2) | Phase 1 / Phase 2 | withdrawn | Oct 4, 2022 | Intima Bioscience, Inc. | No recruitment | Enrollment / accrual |
| NCT06546553 | A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the… | Phase 1 | terminated | Aug 9, 2024 | Pfizer | Study terminated as part of strategic considerations and not based on safety concerns. | Safety / toxicity |
| NCT05233436 | PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic… | Phase 1 | terminated | Feb 10, 2022 | Pfizer | Study terminated based on internal business considerations and was not based on safety reasons | Safety / toxicity |
| NCT05312372 | S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With… | Phase 1 / Phase 2 | withdrawn | Apr 5, 2022 | Institut de Recherches Internationales Servier | Strategic development reasons | Sponsor / business decision |
| NCT05462873 | A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With… | Phase 1 | terminated | Jul 18, 2022 | Novartis Pharmaceuticals | Business decision and not related to safety concerns | Safety / toxicity |
| NCT05551117 | A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant…(Tamarack) | Phase 2 | terminated | Sep 22, 2022 | MacroGenics | Business reasons | Sponsor / business decision |
| NCT04913220 | A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With… | Phase 1 / Phase 2 | terminated | Jun 4, 2021 | Sanofi | Early discontinuation based on strategic sponsor decision not driven by any safety concerns | Safety / toxicity |
| NCT06560645 | A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic… | Phase 1 | terminated | Aug 19, 2024 | Prelude Therapeutics | Sponsor decision | Sponsor / business decision |
| NCT05814666 | Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC(PEMDA-HN) | Phase 2 | terminated | Apr 18, 2023 | Flamingo Therapeutics NV | Interim analysis was negative | Efficacy / futility |
| NCT04163952 | Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or… | Phase 1 | terminated | Nov 15, 2019 | Rutgers, The State University of New Jersey | slow accrual | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated yesterdaySource updated Sep 28, 2026source: clinicaltrials